Article
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting.
Breast cancer research and treatment - 1 Jul 2021
Almodallal Yahya, Le-Rademacher Jennifer G, Cook Kathryn D, Yadav Siddhartha, Singh Amrit B, Lee Minji, Lammert Lisa M, Jatoi Aminah
Abstract excerpt
PURPOSE: Alpelisib is newly-available breast cancer agent that targets PIK3 mutations and confers a somewhat unusual adverse event profile. This study focused on older patients (≥ 65 years of age) treated outside a clinical trial to gain further experience on how these under-studied patients do with this new agent. METHODS: This descriptive, multi-site study relied on medical record review. RESULTS: Fifty-one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.